STX-1 / StarkAge Therap - LARVOL DELTA

STX-1, a first-in-class ADC targeting DPP4 protein, acts as an anticancer and senolytic treatment (AACR 2026) - "However, pretreatment of mice by a combination of Trametinib/Palbociclib induces senescence in tumor, boost expression of DPP4 and allows a better anti-tumor activity of STX-1. To conclude, STX-1 is associated with strong anti-tumor activity in different cancer models, whereas synergistic combination activity to senescence phenotype induction in tumors. The data presented support future clinical development of STX-1 for the treatment of gastric, pancreatic and liver cancer indications."

ADC • Colon Cancer • Colorectal Cancer • Liver Cancer • Mesothelioma • Oncology • Solid Tumor • CTSB • DPP4

New Preclinical Data on STX-1, a First-in-Class Senolytic ADC, To Be Presented at AACR 2026 (GlobeNewswire) - "In the translational poster, StarkAge and Gustave Roussy Institute characterize the impact of treatment-induced senescence in metastatic colorectal cancer and highlight DPP4 (CD26) as a senescence-associated biomarker expressed in both stromal and tumor compartments....In vivo, enhanced activity was observed in senescence-enriched tumors, and STX-1 was reported to be well tolerated in toxicology studies in mice expressing human DPP4."

Preclinical • Colorectal Cancer

STX-1, a potent first-in-class ADC directed against DPP4 (CD26) as a biomarker of senescent tumor cells (AACR 2024) - "This IgG1/k mAb has potent in vitro activities on DPP4+ cells : i) in a bleomycin-induced senescent fibroblasts model; ii) on DPP4-expressing and chemotherapy- or radiotherapy-induced senescent human tumor cell lines with overexpression of DPP4; iii) binding of the mAb to its target results in its internalization into the endolysosomal compartment of cells. Further studies will include optimization of the best STX-1 formulation, NHP studies and GMP scale-up with planned IND submission expected in Q3-2024. Exploiting the targeting of senescent cells in cancer based on selected biomarkers such as DPP4 constitutes a new therapeutic avenue to counteract tumor dormancy, recurrences and resistance to conventional chemo/radiotherapies."

ADC • Biomarker • Tumor cell • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • DPP4

Dipeptidyl peptidase 4 (DPP4) as a new senescence-associated target to eliminate cancer cells (ESMO-TAT 2025) - "Exploiting the targeting of senescent cells in cancer based on selected biomarkers such as DPP4 constitutes a new therapeutic avenue to counteract tumor dormancy, recurrences, and resistance to conventional chemo/radiotherapies. Our results highlight that STX-1 is a first-in-class ADC suitable for the therapeutic targeting of several cancer indications alone and using synergistic combinations."

Oncology • DPP4